LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added ...

The recapitalization will accelerate Curium’s strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the world BOSTON, Nov. 20, 2025 (GLOBE ...

The acquisition of Nucleis will: Enhance Curium's PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of ...

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...

ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium Tc 99m ...

PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which ...

ST. LOUIS, July 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has submitted its 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection ...

BUFFALO, N.Y. and TALLAHASSEE, Fla. — New research shows that curium — one of the heaviest known elements — can be manipulated to a larger degree than previously thought. An international team ...

Curium Pharma, the CapVest Partners-backed nuclear medicine imaging company, is poised to field first round bids early next week, people with knowledge of the matter told PE Hub. A process formally ...

New research shows that curium — one of the heaviest known elements — can be manipulated to a larger degree than previously thought. An international team published a study on July 15 in the journal ...